ブリギマドリンを用いた過去の研究に参加した固形腫瘍患者におけるブリギマドリンの長期治療を検証する研究

基本情報

NCT ID

NCT06619509

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

90

治験依頼者名

Boehringer Ingelheim

概要

This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.

対象疾患

介入

依頼者（Sponsor）

実施施設 (9)